NMT.001 / NEUmiRNA Therapeutics - LARVOL DELTA

Paving the Way for a Unique Disease-Targeting Clinical Program for Drug-Resistant Epilepsy Patients: Initial Safety Studies Demonstrate Adequate Safety Margins of First-in-Class RNA Therapy NMT.001 (AES 2025) - "NMT.001 has the unique potential to target the disease rather than the symptoms. It has demonstrated unprecedented preclinical efficacy, favourable safety margins in the DRF mouse and NHP studies. Upcoming clinical evaluation will now assess safety, PK/PD and preliminary efficacy in patients with focal DRE."

Clinical • Late-breaking abstract • CNS Disorders • Epilepsy • MIR134

Beyond Seizure Suppression: Effect of a miR-134 Antagonist (NMT.001) on Epilepsy-Related Comorbidities (AES 2025) - "Mice were stereotactically injected with KA or PBS, followed by lorazepam to abort status epilepticus. Beyond its established anti-seizure effects, NMT.001 demonstrated beneficial effects on behavioral and cognitive impairments in a mouse model of DRE. These results support miR-134 as a promising therapeutic target with the potential to modify both seizures and associated comorbidities. The findings underline the need to assess epilepsy therapeutics not only by seizure suppression but also by their capacity to address broader neurobehavioral dysfunction."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Epilepsy • Mood Disorders • Psychiatry • MIR134

Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological Disorders (GlobeNewswire) - "Angelini Ventures..today announces that it has co-led a €20 million Series A financing round in Neumirna Therapeutics, an RNA-focused biotech company developing next-generation therapeutics for neurological disorders...The proceeds of the Series A financing will enable Neumirna to advance its lead asset NMT.001 for the treatment of epilepsy into clinical development bringing NMT.001 towards clinical validation. Proceeds will also expand its R&D capabilities and scale its pioneering platform."

Financing • CNS Disorders • Epilepsy